Vaccine Maker Plummets

Novavax falls 24%, cites "substantial doubt" it can stay in business through next year.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Good morning Wake-Up Watchlisters! While you're sipping coffee you'll see stock futures rose on Wednesday to kick off March. Traders are looking to recover their footing after a losing last month. Right now the markets are rising due to a few factors, one being the current economic data out of China, which showed manufacturing PMI rose to 52.6 in February – a high not seen since April 2012. With the markets still in flux to start 2023, it's crucial to use the best strategies to make gains. We use what we call "The Perfect Timing" pattern in the War Room. This simple chart can be learned in under a day, yet it's proven to help traders feel more confident in their trading. Click here to see how this pattern works. Here's a look at the top-moving stocks this morning. Novavax (Nasdaq: NVAX) Novavax is down 24.41% premarket after the vaccine maker warned of "substantial doubt" it can stay in business through next year. Novavax's stock lost 93% of its value as the company faced manufacturing issues last year. Sales from its latest quarter totaled $357 million, with an adjusted loss per share of $2.28. Top and bottom line results missed analysts expectations. If a company is in serious jeopardy, it's crucial to know why. It's also crucial to learn which stocks actually have a chance of increasing value over time. Right now there's a company that our Head Fundamental Tactician Karim Rahemtulla is calling "The Last Great Value Stock." It recently developed an incredible new tech that powers 1 million homes, and its currently trading at under $1. Click here to see why this company is a potential great value play. Sarepta Therapeutics (Nasdaq: SRPT) Sarepta Therapeutics is up 20.24% premarket after topping revenue estimates. The biomedical company posted revenues of $258.43 million for the quarter ending in December 2022, surpassing the Zacks Consensus Estimate by 3.63%. This compares to year-ago revenues of $201.46 million. But overall, shares of Sarepta Therapeutics have lost about 8.8% since the beginning of the year versus the S&P 500's gain of 3.7%. Cutting edge health companies are constantly looking to create the next big breakthrough in medical science. Our friend Alexander Green wants readers to know about this one company. Its already seen over $400 million in investments from the Bill & Melinda Gates Foundation and Fidelity. Plus, Elon Musk recently sent its device into orbit. Click here to discover this under $3 medical device company. Bestselling Financial Author Warns: How to Protect Your Money From China's Evil Plot to Destroy America The man CNBC calls "the Market Maven," who has consulted with several of the world's billionaires and political leaders... Just issued a rare warning urging investors to immediately protect their money... Before China can fully execute their sinister plot to destroy America. Smart investors should watch this video NOW to receive all the important details on this looming crisis. [SEE THE URGENT DETAILS] Rivian Automotive, Inc. (Nasdaq: RIVN) Rivian Automotive is down 9.17% premarket. The electric vehicle company issued production guidance of 50,000 vehicles for 2023, which was below analysts expectations of 62,797. Its revenue for the latest quarter came in at $663 million versus expectations of $717.3 million. It also announced it will recall 12,716 vehicles because of a sensor issue. The Electric Vehicle market is expected to be worth $7 trillion in the coming years. And there's one $25 startup our friend Andy Snyder wants you to know about. Inc. magazine called it "Tesla's worst nightmare" and it's easy to see why. Its car has a 1,080-horsepower engine and a top speed of nearly 170 miles per hour. Yet it's 100% electric. If you missed out on Tesla, click here to learn more about this $25 EV startup. Kohl's Corporation (NYSE: KSS) Kohl's is down 12.05% premarket after posting a fourth quarter net sales decrease of 7.2% and comparable sales decrease of 6.6%. Its gross margin as a percentage of net sales was 23%, a decrease of 1,016 basis points. Clearance markdowns impacted margin by approximately 750 basis points. Those are the biggest stock movers for today. Happy trading! The Wake-Up Watchlist Research Team Most Sales for a Stock Under $5? Check out this chart. One is IBM. One is Facebook (META). One is Tesla. And that big red one to the right with far more sales than the other three? That's a virtually unknown stock that trades under a secret name. Monument Traders Alliance   You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2023 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.